Nautilus Biotechnology Regains Nasdaq Compliance After Transfer to Capital Market
I'm PortAI, I can summarize articles.
Nautilus Biotechnology Inc. has regained compliance with Nasdaq's minimum bid price requirement after transferring to the Nasdaq Capital Market. The company received notice on November 3, 2025, confirming its closing bid price met or exceeded $1.00 for at least ten consecutive business days. Consequently, Nautilus remains listed on The Nasdaq Capital Market, closing the matter regarding its previous non-compliance.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments